Targeting protein degradation to treat advanced childhood tumors
Official title: PROTECT - Harnessing PROTEin degradation for Advanced Childhood Tumors
Funded at University of Oxford · NIH-11047933 · Data updated 2026-11-12
This study is working on new ways to treat children with tough-to-treat brain tumors by focusing on specific proteins that help these cancers grow, using cutting-edge techniques to find better treatments that can improve their chances of recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oxford NIH-funded |
| Lab location | 1 site (Oxford, United Kingdom) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $101,568 |
| NIH project number | 1OT2CA297644-01 |
| Project ID | NIH-11047933 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years diagnosed with advanced solid tumors, particularly those affecting the brain.
✕Less likely to help
Patients with tumors that do not involve the specific protein targets being studied or those outside the age range of 0-11 years may not benefit from this research.
What this research studies
This research focuses on developing innovative treatments for children with advanced solid tumors, particularly brain tumors, by targeting specific proteins that drive these cancers. Using advanced techniques like CRISPR-Cas9 and targeted protein degradation, the research aims to identify and inhibit proteins that are difficult to target with traditional therapies. The approach involves a collaborative effort from experts in various fields, including pediatric oncology and medicinal chemistry, to create effective treatments tailored for young patients. By understanding the unique biology of pediatric tumors, the research seeks to improve survival rates and treatment outcomes for affected children.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted therapies for children suffering from advanced solid tumors, potentially improving survival rates.
How similar studies have gone: Other research has shown promise in using targeted protein degradation and CRISPR techniques for cancer treatment, indicating that this approach could lead to significant advancements in pediatric oncology.
Where this research is happening
-
University of Oxford
Oxford, United Kingdom Active
Researchers
- Principal investigator: Von Delft, Frank — University of Oxford
- Study coordinator: Von Delft, Frank
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.